Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Last trade$20.21
Day change-$0.79 (-3.76%)
Day range$19.72 – $22.51
Volume2,922,158
Market cap$6.02B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.02B
Price / earnings
62.69×
Price / book
9.42×
Price / sales
5.75×
EV / sales
5.49×
EV / EBITDA
35.4×
Profitability
Earnings per share
$0.33
Return on assets
7.65%
Return on equity
15.02%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.61×
Current ratio
6.71×
Quick ratio
5.84×
Cash ratio
4.19×
Cash flow
Price / cash flow
71.79×
Price / free cash flow
208.32×
Free cash flow
$28.91M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CAI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q4 FY2015 Jun 30, 2015
Q3 FY2015 Mar 31, 2015
Revenue
$275.36M
$263.71M
$216.17M
$292.89M
$216.83M
$181.4M
$865.51M
$817.8M
Cost of revenue
$93.07M
$84.12M
$74.83M
$71.97M
$69.33M
$67.71M
$567.45M
$542.84M
Gross profit
$182.29M
$179.6M
$141.35M
$220.91M
$147.51M
$113.69M
$298.06M
$274.96M
Selling, general and administrative
$129.13M
$120.31M
$104.75M
$100.66M
$93.24M
$106.63M
$207M
$205.17M
Research and development
$33.84M
$32.36M
$31.32M
$31.85M
$21.62M
$25.05M
—
—
Total operating expenses
$162.97M
$152.67M
$136.07M
$132.5M
$114.86M
$131.67M
$222.98M
$221.24M
Operating income
$19.32M
$26.93M
$5.28M
$88.41M
$32.64M
-$17.99M
$75.08M
$53.72M
Interest expense
-$9.25M
-$9.23M
-$12.81M
-$11.36M
-$13.51M
-$19.21M
-$8.61M
-$8.47M
Income before taxes
$16.87M
-$614K
-$644K
$81.96M
$24.33M
-$71.79M
$66.47M
$45.24M
Income taxes
$1.62M
$23K
-$134K
$0
$0
$0
$25.13M
$16.19M
Net income
$15.25M
-$637K
-$510K
$81.96M
$24.33M
-$71.79M
$41.35M
$29.06M
Net income attributable to common shareholders
$15.25M
-$637K
-$510K
$81.96M
$24.33M
-$517.2M
$41.38M
$29.04M
EBITDA
$25.92M
$33.46M
$10.35M
$92.7M
$37.51M
-$11.58M
$75.08M
$69.78M
Basic earnings per share
$0.05
$0.00
$0.00
$0.29
$0.09
-$7.97
$1.72
$1.20
Diluted earnings per share
$0.05
$0.00
$0.00
$0.30
$0.08
-$7.97
$1.68
$1.18
Recent news
Company coverage with links to the original publishers.
In a comparison of two Medical Services sector stocks, BrightSpring Health Services (BTSG) emerges as the better value investment option compared to Caris Life Sciences (CAI). BTSG holds a Zacks Rank of #1 (Strong Buy) with a forward P/E of 35.08 and Value grade of B, while CAI has a Zacks Rank of #3 (Hold) with a forward P/E of 234.70 and Value grade of D. BTSG's superior earnings estimate revisions and more attractive valuation metrics make it the preferred choice for value investors.
Caris Life Sciences reported Q3 2026 earnings of $0.05 per share, beating consensus estimates of $0.03, with a 66.67% earnings surprise. Revenues reached $275.36 million, surpassing estimates by 9.75% and up from $216.83 million year-over-year. The company has beaten consensus estimates for four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Caris Life Sciences (CAI) is expected to report a 62.5% year-over-year decline in earnings for Q3 2026 despite 15.7% revenue growth. With a negative Earnings ESP of -45.46% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has beaten consensus estimates in the last four quarters, but recent analyst revisions suggest bearish sentiment on near-term earnings prospects.
Revvity shares surged 9.1% to $140.19 following upbeat commentary on AI-driven demand for research tools, improved order backlog, and a planned acquisition of Human Cell Design. The company expects quarterly EPS of $1.28 (+8.5% YoY) and revenues of $702.56M (+0.5% YoY). However, consensus EPS estimates have been marginally revised lower over the past 30 days, which could limit further price appreciation.
The Nasdaq 100 fell 0.7% as chip stocks stumbled, with Broadcom cratering 15% despite beating earnings due to weak AI-chip revenue guidance. The Dow Jones rallied 1.7% on defensive and financial strength, while the S&P 500 remained flat. Bitcoin hit a 4-month low at $61,310. Other tech stocks like CrowdStrike, Ciena, and Five Below also declined despite beating estimates, reflecting a 'beat-and-bleed' market dynamic. Healthcare and financial stocks led gains.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Sep 9, 2021
$0.30
Sep 27, 2021
recurring
Jun 9, 2021
$0.30
Jun 25, 2021
recurring
Mar 10, 2021
$0.30
Mar 25, 2021
recurring
Dec 8, 2020
$0.25
Dec 24, 2020
recurring
Sep 10, 2020
$0.25
Sep 25, 2020
recurring
Stock splits
Historical share-structure events and their execution dates.